Loading…
Liquidia Corporation is projected to rise to $103.63 by 2027, a +19% move from its current price of $86.80. LQDA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $84.04 | $86.82 | $89.70 | +0.03% |
| Aug 2 | $82.94 | $86.85 | $90.94 | +0.05% |
| Aug 3 | $82.11 | $86.87 | $91.91 | +0.08% |
| Aug 4 | $81.42 | $86.89 | $92.74 | +0.11% |
| Aug 5 | $80.81 | $86.91 | $93.48 | +0.13% |
| Aug 6 | $80.28 | $86.94 | $94.15 | +0.16% |
| Aug 7 | $79.78 | $86.96 | $94.78 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $79.78 | $86.96 | $94.78 | +0.18% |
| Week 2 | $77.13 | $87.12 | $98.40 | +0.37% |
| Week 3 | $75.19 | $87.28 | $101.32 | +0.56% |
| Week 4 | $73.61 | $87.44 | $103.88 | +0.74% |
| Week 5 | $72.26 | $87.60 | $106.21 | +0.93% |
| Week 6 | $71.07 | $87.77 | $108.38 | +1.11% |
| Week 7 | $70.01 | $87.93 | $110.43 | +1.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Liquidia Corporation is a biopharmaceutical company that develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of PAH and PH-ILD.
In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz.
Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia Corporation, symbol LQDA, is a healthcare stock currently trading at $87.04.
It has a market capitalization of $7.74B and is ranked 1033.
The 30-day range is $68.05 to $111.32, and the stock sits near the upper end of that range, reflecting a bullish short-term posture.
The long-range forecast shows upside through 2050, with rising averages and ROIs, including an average price of $160.34 in 2030 and a maximum of $2,280.03 in 2050.
A major floor 59.6% below — a decisive break under it would weaken the trend.
The nearest floor, 20.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.6% away) — a breakout level to watch.
A major ceiling 17.4% above — clearing it would confirm fresh momentum.
Key LQDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LQDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $86.22 | Buy | $86.16 | Buy |
| MA 10 | $84.51 | Buy | $84.51 | Buy |
| MA 20 | $81.20 | Buy | $81.49 | Buy |
| MA 50 | $72.77 | Buy | $72.61 | Buy |
| MA 100 | $56.49 | Buy | $61.68 | Buy |
| MA 200 | $44.63 | Buy | $49.25 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.97 | Neutral |
| Stoch RSI (14) | 73.22 | Neutral |
| CCI (20) | 95.65 | Neutral |
| Williams %R (14) | -12.51 | Info |
| MACD (12,26,9) | 0.14 | Buy |
| ROC (12) | 13.48 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 87.49 | Sell |
| TRIX (15) | 0.76 | Buy |
| Awesome (5,34) | 7.96 | Buy |
| Ultimate (7,14,28) | 65.73 | Neutral |
| Momentum (10) | 11.53 | Buy |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 87.05 | Sell |
| ADX (14) | 27.09 | Buy |
| ATR (14) | 2.38 | Info |
The 30-day technical picture is BULLISH, with RSI14 at 70.
The stock trades above the SMA50 of $69.18 and above the SMA200 of $42.74, indicating positive momentum.
Support is at $64.01 and resistance at $87.04; the 30-day range is $68.05 to $111.32. The annualized volatility is 70%, indicating high volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $30.00 | $86.80 | $112.78 | 0% | Neutral | |
| $81.20 | $103.63 | $140.70 | +19% | Neutral | |
| $85.99 | $113.58 | $161.08 | +31% | Bullish | |
| $99.51 | $135.26 | $198.40 | +56% | Bullish | |
| $117.82 | $164.23 | $247.79 | +89% | Bullish | |
| $144.79 | $206.53 | $319.34 | +138% | Bullish | |
| $169.52 | $247.08 | $390.48 | +185% | Bullish | |
| $181.17 | $269.48 | $434.37 | +210% | Bullish | |
| $190.96 | $289.60 | $475.34 | +234% | Bullish | |
| $190.40 | $294.17 | $491.01 | +239% | Bullish | |
| $335.46 | $564.39 | $1,010.24 | +550% | Bullish | |
| $587.89 | $1,149.67 | $2,276.08 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $30.00 | $86.80 | $101.36 | +0.00% |
| August 2026 | $73.55 | $86.67 | $104.78 | -0.14% |
| September 2026 | $74.70 | $88.91 | $109.20 | +2.58% |
| October 2026 | $77.04 | $92.44 | $114.96 | +3.97% |
| November 2026 | $75.68 | $91.41 | $114.82 | -1.12% |
| December 2026 | $73.22 | $88.97 | $112.78 | -2.66% |
Click any year to see its month-by-month LQDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect LQDA to range from $30.00 to $112.78 through 2026. The $86.80 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The LQDA price prediction for 2027 points to an average of $103.63 (low $81.20, high $140.70) — a potential gain of +19% on today's $86.80. Price action looks broadly range-bound.
In 2028, LQDA is projected to trade between $85.99 and $161.08, averaging $113.58 — a potential gain of +31% from today's $86.80. That is up +10% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Liquidia Corporation's 2029 outlook centres on $135.26, within a $99.51 to $198.40 range. That is up +19% on the projected 2028 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2030, LQDA could reach as high as $247.79, with a base case around $164.23 and support toward $117.82 — roughly +89% from $86.80. Buyers look set to stay in control over this stretch.
Expect LQDA to range from $144.79 to $319.34 through 2031. The $206.53 average target implies a +138% move from current prices. That is up +26% on the projected 2030 average. Momentum favours further upside here.
The LQDA price prediction for 2032 points to an average of $247.08 (low $169.52, high $390.48) — a potential gain of +185% on today's $86.80. Buyers look set to stay in control over this stretch.
In 2033, LQDA is projected to trade between $181.17 and $434.37, averaging $269.48 — a potential gain of +210% from today's $86.80. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Liquidia Corporation's 2034 outlook centres on $289.60, within a $190.96 to $475.34 range. That is up +7% on the projected 2033 average. That marks a +234% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, LQDA could reach as high as $491.01, with a base case around $294.17 and support toward $190.40 — roughly +239% from $86.80. Momentum favours further upside here.
Expect LQDA to range from $335.46 to $1,010.24 through 2040. The $564.39 average target implies a +550% move from current prices. That is up +92% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The LQDA price prediction for 2050 points to an average of $1,149.67 (low $587.89, high $2,276.08) — a potential gain of +12.2x on today's $86.80. Momentum favours further upside here.
Investing $1,000 in LQDA today (≈ 11.520737 LQDA) could be worth
$13,245.09
+$12,245.09 (+1225%) by 2050 · US Dollar
Based on the average projected LQDA price of $1,149.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LQDAwould be worth at today's price.
$1,000 invested in LQDA on Jul 30, 2025 (≈ 52.328622 LQDA) would be worth
$4,542.12
+$3,542.12 (+354.2%) today · 4.54× · US Dollar
Based on a LQDA entry price of $19.11 vs. today's $86.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $89.03 | $974.95 | -2.5% |
| 1 month ago | $79.73 | $1,088.67 | +8.9% |
| 3 months ago | $38.14 | $2,275.83 | +127.6% |
| 6 months ago | $42.39 | $2,047.65 | +104.8% |
| 1 year ago | $19.11 | $4,542.12 | +354.2% |
| All time (5.0y) ago | $2.36 | $36,779.66 | +3578.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LQDA forecast.
Our base-case forecast reaches $170.00 around 2031.
Implied market cap at $170.00: $15.12B
The multi-year forecast shows a bullish trajectory across years with rising averages and ROIs.
2026 min $30.00, avg $87.04, max $113.57; ROI 0; sentiment NEUTRAL.
2027 min $79.32, avg $103.01, max $143.02; ROI 18.3; sentiment NEUTRAL.
2028 min $80.60, avg $108.93, max $158.76; ROI 25.1; sentiment BULLISH.
2029 min $93.61, avg $130.83, max $197.94; ROI 50.3; sentiment BULLISH.
2030 min $111.37, avg $160.34, max $250.29; ROI 84.2; sentiment BULLISH.
2031 min $134.77, avg $199.41, max $319.81; ROI 129.1; sentiment BULLISH.
2032 min $160.25, avg $243.28, max $399.69; ROI 179.5; sentiment BULLISH.
2033 min $169.08, avg $262.98, max $441.54; ROI 202.1; sentiment BULLISH.
2034 min $171.46, avg $272.96, max $467.51; ROI 213.6; sentiment BULLISH.
2035 min $171.41, avg $279.06, max $486.84; ROI 220.6; sentiment BULLISH.
2040 min $296.76, avg $535.98, max $1,009.25; ROI 515.8; sentiment BULLISH.
2050 min $497.71, avg $1,085.46, max $2,280.03; ROI 1147.1; sentiment BULLISH.
These figures are estimates, not guarantees, and reflect a wide range of possible outcomes.
Tap a question to reveal the answer.
2030 avg $160.34; min $111.37; max $250.29; ROI 84.2%; sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with 2040 avg $535.98 and 2050 avg $1,085.46; ROI reaches 515.8% by 2040 and 1147.1% by 2050.
Yes. The 2027 forecast shows an average price of $103.01.
$68.05 to $111.32.
Current price $87.04; Market capitalization $7.74B.
Liquidia Corporation Community Discussion
0Share your Liquidia Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.